Synthroid Sales Expected To Grow 12% For Year Following NDA Approval

Abbott expects Synthroid growth of approximately 12% in 2002 following approval of the synthetic thyroid hormone replacement therapy's NDA

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet